Mitral bioprosthesis hypertrophic scaring and native aortic valve fibrosis during benfluorex therapy

Fundamental and Clinical Pharmacology

Volumn 26, Issue 2, 2012, Pages 215-218

  Ayme Dietrich, Estelle ^a   Lawson, Roland ^a   Gasser, Bernard ^b   Dallemand, Robert ^b   Bischoff, Nicolas ^b   Monassier, Laurent ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b CENTRE HOSPITALIER DE MULHOUSE   (France)

Author keywords

Adverse drug reaction; Benfluorex; Bioprosthesis; Serotonergic receptors; Valvular heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA SMOOTH MUSCLE ACTIN; AMIODARONE; ATENOLOL; BENFLUOREX; DILTIAZEM; FENOTEROL PLUS IPRATROPIUM BROMIDE; FUROSEMIDE; GLYCOSAMINOGLYCAN; LEVOTHYROXINE; OMEPRAZOLE; PRAVASTATIN; ROSUVASTATIN; TOPIRAMATE; VIMENTIN;

ADULT; AORTA VALVE DISEASE; AORTA VALVE FIBROSIS; AORTA VALVE REGURGITATION; ARTICLE; ATHEROSCLEROTIC PLAQUE; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; EXERCISE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; MITRAL BIOPROSTHESIS HYPERTROPHIC SCARRING; MITRAL VALVE REGURGITATION; MITRAL VALVE REPLACEMENT; OBESITY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSTHESIS FAILURE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSTHORACIC ECHOCARDIOGRAPHY;

ADULT; AORTIC VALVE; BIOPROSTHESIS; CICATRIX, HYPERTROPHIC; FEMALE; FENFLURAMINE; FIBROSIS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; HUMANS; HYPOLIPIDEMIC AGENTS; MITRAL VALVE INSUFFICIENCY;

EID: 84858080134     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2012.01027.x     Document Type: Article

References (15)

1. Thevis M., Sigmund G., Gougoulidis V. et al. Screening for benfluorex and its major urinary metabolites in routine doping controls. Anal. Bioanal. Chem. (2010) 401 543-551.
2. Bhattacharyya S., Schapira A.H., Mikhailidis D.P., Davar J. Drug-induced fibrotic valvular heart disease. Lancet (2009) 374 577-585.
3. Setola V., Hufeisen S.J., Grande-Allen J. et al. 3, 4-methylenedioxymethamphetamine (MDMA, "ecstasy") induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. (2003) 63 1223-1229.
4. Barzilla J.E., Acevedo F.E., Grande-Allen J. Organ culture as a tool to identify early mechanisms of serotonergic valve disease. J. Heart Valve Dis. (2010) 19 626-635.
5. Orsière T., Chauvet M., Dell'Amico M. et al. In vitro influence of benfluorex and its main metabolites on rat liver microsomal membranes properties. Chem. Biol. Interact. (1995) 97 297-306.
6. Boutet K., Frachon I., Jobic Y. et al. Fenfluramine-like cardiovascular side-effects of benfluorex. Eur. Respir. J. (2009) 33 684-688.
7. Etienne Y., Jobic Y., Frachon I. et al. Mitral and aortic valvular disease associated with benfluorex use. J. Heart Valve Dis. (2011) 20 348-350.
8. Bhattacharyya S., Davar J., Dreyfus G., Caplin M.E. Carcinoid heart disease. Circulation (2007) 116 2860-2865.
9. Elangbam C.S., Lightfoot R.M., Yoon L.W. et al. 5-hydoxytryptamine (5-HT) receptors in the heart valves of cynomolgus monkeys and Sprague-Dawley rats. J. Histochem. Cytochem. (2005) 53 671-677.
10. Droogmans S., Kerkhove D., Cosyns B., Van Camp G. Role of echocardiography in toxic heart valvulopathy. Eur. J. Echocardiogr. (2009) 10 467-476.
11. Centers for Disease Control and Prevention (CDC). Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of health and human services interim public health recommendations, November 1997. MMWR Morb. Mortal. Wkly Rep. (1997) 46 1061-1066.
12. Van Camp G., Flamez A., Cosyns B. et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet (2004) 363 1179-1183.
13. Connolly H.M., Crary J.L., Mc Goon M.D. et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. (1997) 337 581-588.
14. + cells during the early intraperitoneal foreign body reaction. Biomaterials (2008) 29 797-808.
15. Visconti R.P., Ebihara Y., LaRue A.C. et al. An in vivo analysis of hematopoietic stem cell potential. Hematopoietic origin of cardiac valve interstitial cells. Circ. Res. (2006) 98 690-696.